The Wistar Institute Proteomics Facility

Karen Ziemann

🇸🇦 Saudi Arabia

9.1

Reviewed: April 6, 2024

• - HTA Submission
• - 8 weeks February - March 2024
• - Biotech Company

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Cristina Ferry

🇺🇸 United States

5.6

Reviewed: February 20, 2024

• - Clinical Data Management
• - 8 weeks December 2023 - February 2024
• - Biotech Company

The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.

Dr. Heather Kautzer

🇸🇦 Saudi Arabia

9

Reviewed: February 4, 2024

• - Biomarker Development
• - 12 weeks October 2023 - January 2024
• - Research Institution

The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.

Candice Hane

🇨🇦 Canada

6.5

Reviewed: July 18, 2024

• - Regulatory Submission
• - 8 weeks May - July 2024
• - Pharmaceutical Company

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Ada Hessel

🇺🇸 United States

6.2

Reviewed: March 15, 2024

• - Clinical Protocol Design
• - 10 weeks January - March 2024
• - Pharmaceutical Company

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Ginger Abshire-Bauch

🇸🇦 Saudi Arabia

9

Reviewed: June 18, 2023

• - Clinical Protocol Design
• - 6 weeks April - May 2023
• - Pharmaceutical Company

The protocol design provided was comprehensive and very detailed. It laid a strong foundation for our clinical trial, ensuring that all regulatory and ethical considerations were addressed. The attention to detail was impressive.

Mr. Oliver Braun III

🇯🇵 Japan

5.4

Reviewed: October 3, 2024

• - Process Development
• - 14 weeks June - September 2024
• - Biotech Company

The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.

Sonya Yost

🇨🇭 Switzerland

6

Reviewed: September 12, 2024

• - Health Technology Assessment
• - 8 weeks July - September 2024
• - Pharmaceutical Company

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.